The limits of innovation: Directly addressing known challenges is necessary to improve the real‐world experience of novel medications for opioid use disorder-Reference-Cited by-同舟云学术

The limits of innovation: Directly addressing known challenges is necessary to improve the real‐world experience of novel medications for opioid use disorder

Published:2023-10-28 Issue:12 Volume:30 Page:1285-1287
ISSN:1069-6563
Container-title:Academic Emergency Medicine
language:en
Short-container-title:Academic Emergency Medicine

Author:

Morgan Jake R.¹^ORCID,Assoumou Sabrina A.²

Affiliation:

1. Department of Health Law, Policy, and Management Boston University School of Public Health Boston Massachusetts USA

2. Department of Medicine Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA

Funder

National Institute on Drug Abuse

Publisher

Wiley

Subject

Emergency Medicine,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/acem.14814

Reference17 articles.

1. Early emergency department experience with 7‐day extended‐release injectable buprenorphine for opioid use disorder

2. Indivior UK Limited.Sublocade Package Insert. Updated 2 Feb 2020. Accessed August 1 2023.https://www.sublocade.com/Content/pdf/prescribing‐information.pdf

3. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort

4. Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Buprenorphine/naloxone – one formulation that doesn’t fit all: a case report;Harm Reduction Journal;2024-07-30

2. Buprenorphine/naloxone – One formulation that doesn’t fit all: A case report;2024-05-06

3. Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence;International Journal of Drug Policy;2024-04